Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Feb-Mar;25(2-3):89-93.
doi: 10.1007/s10815-008-9203-8. Epub 2008 Feb 6.

Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients

Candan Iltemir Duvan  1 , Bulent Berker, Nilgun Ozturk Turhan, Hakan Satiroglu
Affiliations
Comparative Study

Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients

Candan Iltemir Duvan et al. J Assist Reprod Genet. 2008 Feb-Mar.

Abstract

Purpose: To compare oral contraceptive (OC) pretreatment plus microdose GnRH-a in flare-up protocol and non-OC microdose GnRH-a in flare-up protocol among poor responder ICSI patients.

Methods: A retrospective analysis of poor responder ICSI patients. Patients were divided into two groups according to used microdose protocol. Precycle treatment with OC followed by follicular phase administration of 40 microg s.c. leuprolide acetate (LA) every 12 h beginning on after 2 day pill-free period and rFSH administration was begun on the third day of LA administration (OC-Group, n=26). Alternatively on day 2 after menses, patients were administered similar stimulation regime (non-OC Group, n=27).

Results: There were no significant differences between groups in the number of oocytes, peak estradiol levels, endometrial thickness, fertilization rates and embryo quality. Implantations and pregnancy rates per embryo transfer were similar.

Conclusion: OC pretreatment plus microdose GnRHa in flare-up protocol does not offer advantages over non-OC microdose GnRHa in flare-up protocol among poor responder ICSI patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0015-0282(97)00575-X', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0015-0282(97)00575-x'}, {'type': 'PubMed', 'value': '9531870', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9531870/'}]}
    2. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 1998;69(3):419–24. Mar. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '1761658', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/1761658/'}]}
    2. Jenkins JM, Davies DW, Devonport H, Anthony FW, Gadd SC, Watson RH, Masson GM. Comparison of ‘poor’ responders with ‘good’ responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization. Hum Reprod. 1991;6(7):918–21. Aug. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/BF01131588', 'is_inner': False, 'url': 'https://doi.org/10.1007/bf01131588'}, {'type': 'PubMed', 'value': '1826724', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/1826724/'}]}
    2. Ben-Rafael Z, Bider D, Dan U, Zolti M, Levran D, Mashiach S. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRH-a/hMG) in normal, high, and poor responders to hMG. J In Vitro Fert Embryo Transf. 1991;8(1):33–6. Feb. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8174725', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8174725/'}]}
    2. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril. 1994;61(5):880–5. May. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8059833', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8059833/'}]}
    2. Tan SL, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, Brinsden P, Edwards RG, Jacobs HS. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol. 1994;171(2):513–20. Aug. - PubMed

Publication types

LinkOut - more resources